Inovio Q1 net loss $19.7M ($0.28/shr); cash runway into Q1 2027 beyond Oct PDUFA

INOVIO PHARMACEUTICALS, INC.

2026-Q1 EPS reported -$0.28

Net loss $19.7M, flat YoY; diluted EPS ($0.28) vs ($0.51) due to fewer shares.
Revenue not reported (pre-revenue biotech); R&D spend $14.1M (-12% YoY), G&A $7.9M (-12%).
Cash & equivalents $37.7M at Mar 31, plus $16M from April offering; expects ops into Q1 2027.
FDA reviewing INO-3107 BLA under accelerated approval; PDUFA date Oct 30, 2026.
Collaboration with Akeso to test INO-5412 + cadonilimab in GBM in Dana-Farber INSIGhT trial.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INOVIO PHARMACEUTICALS, INC. reported financial results for the three months ended March 31, 2026.

Period: the three months ended March 31, 2026
Result: reported results

Exact text from the filing

On May 13, 2026, Inovio Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

INOVIO PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001055726-26-000019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.